Advanced searches left 3/3

Placebo - Springer Nature

Summarized by Plex Scholar
Last Updated: 26 September 2022

* If you want to update the article please login/register

Evaluation of Lactocare® Synbiotic Administration on the Serum Electrolytes and Trace Elements Levels in Psoriasis Patients: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Study

In this research, Lactocareu00ae synbiotic's effect on the serum levels of trace elements including Zn, Cu, Mg, Na, Fe, P, Ca, and K in patients with mild to moderate psoriasis was investigated. Because of the new COVID-19 disease, eight patients from the intervention group and 18 patients from the control group suspended the study. The blood samples were obtained from all patients at the baseline and week 12 post-treatment for routine trace element analysis. Conclusions The placebo group's serum K, P, and Ca levels were significantly higher than those in the treatment group at baseline. At week 12 post-treatment, Zn and Ca serum levels were dramatically higher in the treatment group relative to the placebo group. In addition, a significantly reduced serum level of K, P, and Ca in the treatment group at the baseline relative to the placebo group was compensated on week 12 post-treatment. Fe, Ca, Mg, P, Zn, P, Zn, and Na serum levels were significantly elevated at week 12 post-treatment as compared to baseline values, according to a team's intra-group analysis. Whereas, intra-group analysis in the control group revealed that only Ca had a significant difference between baseline and week 12 post-treatment, with no difference between baseline and week 12 post-treatment. Conclusion Fe, Zn, P, Mg, Ca, and Na have all increased significantly 12 weeks after oral administration of Lactocare®u00ae in psoriatic patients. Fe and Cu's serum levels are affected by sex both pre- and post-treatment.

Source link: https://doi.org/10.1007/s12011-021-03020-6


Safety evaluation and biochemical efficacy of celery seed extract (Apium Graveolens) capsules in hypertensive patients: a randomized, triple-blind, placebo-controlled, cross-over, clinical trial

In hypertensive patients, the present research was done to determine the effectiveness of celery seed extract, as a medicinal herb with active ingredients such as 3-n-butylphthalide. As an addition to their normal medication regimen, hypertensive patients received 4 celery seed capsules or 4 placebo capsules per day for four weeks. The celery seed capsule not only was safe for hypertensive patients but also led to a decline in BP, FBS, and lipid profile measurements, according to the study.

Source link: https://doi.org/10.1007/s10787-022-00986-0


Maternal and infant probiotic administration for morbidity of very low birth weight infants: a three-arm randomized placebo-controlled trial

Objectives: To determine whether oral probiotic supplementation to breastfeeding mothers or infants with very low birth weight infants will reduces total serum bilirubin level and infant weight gain. The TSB level was not significantly different among the three groups on the threerd day of intervention, but on the 7th day, it was significantly lower in the two probiotic groups compared to the placebo group. During the 8thu201328th days, mean rank of infant weight gain during the first 7 days of intervention was noticeably higher in both maternal and infant probiotic groups compared to the placebo group, but there was no statistically significant difference between the two groups during the 8thu201328th days. After the first week of the experiment, Lacticasebacillus senibacillus casei, breastfeeding mothers of VLBW infants or infants, have no effect on weight gain.

Source link: https://doi.org/10.1007/s00394-022-02905-z


Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

This 12-minute walking test distance was used to determine whether burosumab's benefits were evident in 14 clinically relevant subgroups characterized by baseline demographic and functional variables, including sex, Brief Pain Inventory-short form, Western Ontario and McMaster Universities. In both subgroups, higher proportions of subjects achieved mean serum phosphate concentrations above the lower limit of average with burosumab than with placebo. Burosumab was mostly superior to placebo across endpoints in the 14 clinically relevant subgroup variables at 24 weeks, according to this subgroup study, and it is likely to benefit all symptomatic adults with active XLH.

Source link: https://doi.org/10.1007/s00223-022-01006-7


Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone

Alcohol use disorder is characterized by a lack of control over alcohol use disorder. Inhibition of catechol-O-methyltransferase, the enzyme that is primarily responsible for cortical dopamine inactivation, may cause cortical dopamine production, particularly among people with genetically altered lower dopaminergic tone, such as COMT rs4680 val-allele homozygotes. Participants in a baseline and on day 7 were surprised, and participants completed a fMRI alcohol cue-reactivity task; on day 8, they completed a bar-lab approach. Tolcapone's effect on drinking during the medication period and in the bar lab was modest, with only val-allele homozygotes reduced drinking among val-allele homozygotes. Cue-elicited ventral activation was not influenced by Tolcapone's reduced rIFG signaling, but it did not affect reduced rIFG activation on day 7 because of less drinking during the medication period. These findings, taken together, show that COMT inhibition may reduce drinking specifically among individuals genetically linked to elevated COMT levels and possibly low cortical dopamine tone.

Source link: https://doi.org/10.1038/s41386-022-01335-z


The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Using the EuroQol 5-Dimension 5-Level Index and Visual Analog Scale, we explore the effects of guselkumab on health-related quality of life through Week 52. Methods Adults with active PsA were randomized to guselkumab 100 mg every four weeks, four weeks, or placebo. Changes in the EQ-5D-5L Index and EQ-VAS from baseline to Week 52 were measured by Least squares. With pooled results through Week 24, an association of patient clinical features and the EQ-5D-5L Index and EQ-VAS scores were investigated cross-sectionally. In Q4W, 56% in Q8W, and 61. 1 percent in the placebo crossover group at Week 52, 56. 0 percent were achieved by 56. 6 percent, with 56. 2% in each guselkumab group, 66% in Q8W, and 62% in placebo crossover group at Week 52. A higher tender joint count was correlated with lower EQ-5D-5L, and lower swollen joint count was correlated with lower EQ-VAS. Conclusions Guselkumab boosted HRQoL in patients with active PsA for 52 weeks.

Source link: https://doi.org/10.1007/s12325-022-02269-0


The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Those with psoriatic arthritis have a tendency to suffer work efficiency and nonwork in biologic-nau00efve patients with psoriatic arthritis, according to the phase 3 DISCOVER-2 trial. Methods Adults with Active PsA were given randomized guselkumab 100 mg every four weeks, guselkumab 100 mg at weeks 0 and 4, or placebo, with placebo at week 0 and 4, as well as every 8 weeks. The treatment group determined the most change from baseline in the Work Productivity and Activity Impairment Questionnaire for PsA domains and positions at work. Independent studies from weeks 0 to 24 identified causal links between PsA clinical characteristics and WPAI-PsA domains. Both guselkumab and nonwork impairment in patients with active PsA can be reduced in job quality and nonwork activity. With PsA's joint and skin improvements, increased work efficiency improvement and nonwork impairment can be beneficial for optimizing increased work quality loss and nonwork impairment.

Source link: https://doi.org/10.1007/s12325-022-02270-7


Multiple platelet-rich plasma injections are superior to single PRP injections or saline in osteoarthritis of the knee: the 2-year results of a randomized, double-blind, placebo-controlled clinical trial

Introduction The primary objectives of this research were to establish the safety of multiple doses compared to a single dose and determine the effectiveness of PRP injection therapy on knee pain and functions by comparing patients with mild to moderate OA with a placebo control group and discovering the safety of multiple doses relative to a single dose. The following were randomly divided into four groups: single dose of PRP, single dose of sodium saline, three doses of PRP, three doses of PRP, three doses of PRP, three doses of PRP, and three doses of NS were randomly divided into four groups. Pre-treatment and at 1, 3, 6, 12 and 24 months post-treatment, using the Knee Injury and Osteoarthritis Result Score, knee joint range of motion, measurements of knee circumference, and a Visual Analog Scale were used to analyze pain, as well as a Visual Analog Scale for pain analysis. Patients treated with PRP had higher scores at 3, 6 and 12 months than the NS groups. Multiple doses of PRP were found to be more effective than single-dose PRP at 6 and 12 months. Patients with stage 2 OA showed the most encouraging improvement in scores, with the most encouraging change in ROM in stage 3 OA patients. Multiple doses of PRP can improve the treatment's safety and duration. Patients aged 51u201365 years, with lower MAA, and by K/L stage 2 OA patients were among PRP patients treated with PRP.

Source link: https://doi.org/10.1007/s00402-021-04230-2


Expectancy in placebo-controlled trials of psychedelics: if so, so what?

Modern psychedelic research is still in its early stages, and the eventual introduction of psychedelics into clinical practice is uncertain. We explore the role of blinding and anticipation in psychedelic trials in this book, as well as the wider historical and modern context of blinding in trials around the rest of healthcare. Participation in ongoing psychedelic trials is not limited to misleading or uncritical promotion of psychedelics as drugs, but it also directly influences participant expectations. Although psychotherapeutic trials are expected to significantly underestimate treatment results by design due to unblinding and expectancy effects, this is not a unique occurrence. Placebo-controlled RCTs are not a good match for all therapeutics, and blindness should not disqualify medications from licencing decisions. Naturalistic studies are among the alternate trial methods that might be used to support RCT results. We briefly discuss other alternative trial designs that may be used to support RCT results.

Source link: https://doi.org/10.1007/s00213-022-06221-6

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions